Resolution CM/Res(2016)2 and Centralised Intra Venous Additive Services (CIVAS): Challenges and Opportunities
| Autor: | Sandy Vrignaud |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pharmacology
business.industry Resolution (electron density) resolution cm/res(2016)2 risk assessment RM1-950 Pharmacy civas 010402 general chemistry 030226 pharmacology & pharmacy 01 natural sciences 0104 chemical sciences injectable preparation 03 medical and health sciences 0302 clinical medicine hospital pharmacy services Medicine Pharmacology (medical) Therapeutics. Pharmacology HD9665-9675 business Pharmaceutical industry Remote sensing |
| Zdroj: | Pharmaceutical Technology in Hospital Pharmacy, Vol 2, Iss 3, Pp 137-142 (2017) |
| ISSN: | 2365-242X 2365-2411 |
| DOI: | 10.1515/pthp-2017-0023 |
| Popis: | The aim of the European Council’s Resolution CM/res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use is to guide the health care establishment’s decision as to where reconstitution should take place: in the pharmacy or the clinical area. Injectable preparation in hospital pharmacy is performed in Centralised Intra Venous Additive Services (CIVAS). Nevertheless, challenges such as ensuring the sterility of the preparation, the physicochemical stability of the product, and process validation for instance should be taken into account. This opinion paper examines the challenges, impacts, and responsibilities for pharmacists, nurses, and hospital management related to implementing the resolution, regarding the experience of countries where CIVAS are already implemented. It also discusses the opportunities of implementing CIVAS with regard to patient care safety and potential financial savings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|